RE:RE:MindMed MMED vs BetterLife BETR Don't stand in the wind get BetterLife before to late. You will be kicking yourself in the face when BETR jumps 20X or old highs $28. Here is why:
BetterLife Pharma (CSE: BETR) gained by 30.4% today to $1.63 per share on record volume of 872,059 shares. After acquiring Transcend Biodynamics LLC today, BETR now has 50,349,359 shares outstanding for a market cap of US$64.45 million. Currently, MindMed (MMEDF) is the only well known LSD play, which has caused its market cap to rise to well over US$1 billion. The odds of MMEDF getting approved to conduct FDA trials in the U.S. are low and the cost would be astronomical. BETR is the only entity with the ability to synthesize BOL-148 without the regulatory hurdles of handling a Schedule 1 controlled substance. BOL-148 is a nontoxic second-generation LSD-derived molecule that mimics the therapeutic potential of LSD, without the hallucinations. BETR will be developing a pipeline of psychedelic therapeutics including LSD based pharmaceutical treatments.